Zelluna Therapeutics has appointed its new chief executive officer in the form of Miguel Forte.
His new role will see him lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.
Forte said: “Zelluna has a very strong foundation, based on over 30 years of cutting edge research.
“I wished to join Zelluna to combine my experience to the considerable potential of Zelluna to position is as an international immunotherapy leader and bringing serious therapeutic options to patients of the most common and fatal solid cancers.”
Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, Bristol-Myers Squibb, Abbott, and UCB to name a few.
Forte’s expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and is currently chief commercialisation officer and chair of the commercialisation committee for the International Society of Cellular Therapy.
Anders Tuv, chairman of the board, Zelluna, said: “Appointing a CEO with the international experience and profile of Miguel Forte will be critical to further enhance the therapeutic development and commercial potential of Zelluna, and push its leadership position in the international TCR and immunotherapy marketplaces.”